Conestoga Capital Advisors LLC Purchases 36,850 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Conestoga Capital Advisors LLC boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,978,351 shares of the medical instruments supplier's stock after purchasing an additional 36,850 shares during the quarter. LeMaitre Vascular comprises approximately 2.5% of Conestoga Capital Advisors LLC's holdings, making the stock its 16th largest position. Conestoga Capital Advisors LLC owned about 8.81% of LeMaitre Vascular worth $183,769,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock worth $21,740,000 after purchasing an additional 90,573 shares during the period. F M Investments LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at approximately $7,443,000. Nicholas Investment Partners LP acquired a new position in LeMaitre Vascular in the 2nd quarter valued at approximately $3,900,000. Janus Henderson Group PLC lifted its position in shares of LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier's stock worth $3,697,000 after acquiring an additional 47,218 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier's stock worth $87,914,000 after purchasing an additional 38,303 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Wall Street Analyst Weigh In

LMAT has been the subject of several research reports. Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research report on Friday. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price objective for the company. JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 20th. Lake Street Capital started coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a "buy" rating and a $105.00 price target for the company. Finally, Oppenheimer reiterated an "outperform" rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $94.57.

Insider Activity

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the company's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Up 7.3 %

NASDAQ:LMAT traded up $6.49 during mid-day trading on Friday, reaching $94.88. 343,615 shares of the company were exchanged, compared to its average volume of 123,348. The stock has a market cap of $2.13 billion, a PE ratio of 59.86, a PEG ratio of 2.33 and a beta of 0.88. LeMaitre Vascular, Inc. has a 12 month low of $45.96 and a 12 month high of $101.67. The company has a fifty day moving average of $89.53 and a 200 day moving average of $82.77.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $54.82 million for the quarter, compared to analysts' expectations of $53.50 million. During the same period in the prior year, the firm earned $0.33 earnings per share. LeMaitre Vascular's revenue was up 15.6% compared to the same quarter last year. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.86 EPS for the current fiscal year.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.